Sino Biopharmaceutical Li... (SBHMY)
Sino Biopharmaceutical Statistics
Share Statistics
Sino Biopharmaceutical has 951.19M shares outstanding. The number of shares has increased by 1.42% in one year.
| Shares Outstanding | 951.19M |
| Shares Change (YoY) | 1.42% |
| Shares Change (QoQ) | 1.42% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 14 |
| FTD / Avg. Volume | 17.95% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 33.5 and the forward PE ratio is null. Sino Biopharmaceutical's PEG ratio is -0.47.
| PE Ratio | 33.5 |
| Forward PE | n/a |
| PS Ratio | 2.98 |
| Forward PS | n/a |
| PB Ratio | 2.56 |
| P/FCF Ratio | 17.91 |
| PEG Ratio | -0.47 |
Enterprise Valuation
Sino Biopharmaceutical has an Enterprise Value (EV) of 1,565.4B.
| EV / Sales | 59.75 |
| EV / EBITDA | 224.28 |
| EV / EBIT | 258.07 |
| EV / FCF | 358.86 |
Financial Position
The company has a current ratio of 1.05, with a Debt / Equity ratio of 0.41.
| Current Ratio | 1.05 |
| Quick Ratio | 0.96 |
| Debt / Equity | 0.41 |
| Debt / EBITDA | 1.8 |
| Debt / FCF | 2.88 |
| Interest Coverage | 11.68 |
Financial Efficiency
Return on Equity is 7.65% and Return on Invested Capital is 9.45%.
| Return on Equity | 7.65% |
| Return on Assets | 3.67% |
| Return on Invested Capital | 9.45% |
| Revenue Per Employee | $1,074,671.19 |
| Profits Per Employee | $95,653.6 |
| Employee Count | 24,379 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 2.5 |
Taxes
| Income Tax | 797.27M |
| Effective Tax Rate | 14.74% |
Stock Price Statistics
The stock price has increased by 31.67% in the last 52 weeks. The beta is 0.75, so Sino Biopharmaceutical's price volatility has been higher than the market average.
| Beta | 0.75 |
| 52-Week Price Change | 31.67% |
| 50-Day Moving Average | 8.75 |
| 200-Day Moving Average | 8.27 |
| Relative Strength Index (RSI) | 64.18 |
| Average Volume (20 Days) | 78 |
Income Statement
In the last 12 months, Sino Biopharmaceutical had revenue of 26.2B and earned 2.33B in profits. Earnings per share was 1.58.
| Revenue | 26.2B |
| Gross Profit | 21.21B |
| Operating Income | 5.79B |
| Net Income | 2.33B |
| EBITDA | 6.98B |
| EBIT | 5.91B |
| Earnings Per Share (EPS) | 1.58 |
Balance Sheet
The company has 9.45B in cash and 12.58B in debt, giving a net cash position of -3.13B.
| Cash & Cash Equivalents | 9.45B |
| Total Debt | 12.58B |
| Net Cash | -3.13B |
| Retained Earnings | 29.34B |
| Total Assets | 66.7B |
| Working Capital | 3.27B |
Cash Flow
In the last 12 months, operating cash flow was 6.07B and capital expenditures -1.7B, giving a free cash flow of 4.36B.
| Operating Cash Flow | 6.07B |
| Capital Expenditures | -1.7B |
| Free Cash Flow | 4.36B |
| FCF Per Share | 0.19 |
Margins
Gross margin is 80.95%, with operating and profit margins of 22.08% and 8.9%.
| Gross Margin | 80.95% |
| Operating Margin | 22.08% |
| Pretax Margin | 20.65% |
| Profit Margin | 8.9% |
| EBITDA Margin | 26.64% |
| EBIT Margin | 22.08% |
| FCF Margin | 16.65% |
Dividends & Yields
SBHMY pays an annual dividend of $0.21, which amounts to a dividend yield of 1.93%.
| Dividend Per Share | $0.21 |
| Dividend Yield | 1.93% |
| Dividend Growth (YoY) | -49.99% |
| Payout Ratio | 70.76% |
| Earnings Yield | 2.99% |
| FCF Yield | 0.28% |
Analyst Forecast
Currently there are no analyst rating for SBHMY.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Sep 4, 2020. It was a forward split with a ratio of 3:2.
| Last Split Date | Sep 4, 2020 |
| Split Type | forward |
| Split Ratio | 3:2 |
Scores
| Altman Z-Score | 1.54 |
| Piotroski F-Score | 6 |